Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New digital scope could help rectal cancer patients avoid surgery

NCT ID NCT06189846

Diagnosis Sponsor: Bordeaux Colorectal Institute Academy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new digital scope called LUMENEYE to see if it can better measure how much a rectal tumor has shrunk after chemotherapy and radiation. 82 patients who were good candidates for organ preservation were included. The goal was to see if the scope could help doctors decide who can safely skip surgery and keep their rectum.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LUMENEYE rectoscope (a digital endoscope device)
What this could lead to
If successful, this could help doctors more accurately decide which rectal cancer patients can safely avoid surgery and preserve their rectum after chemotherapy and radiation.
What could go wrong
This is a small, completed observational study (82 people) that only measures how well the device agrees with standard tests. It does not test a new treatment or prove long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

82 people

The number who actually took part.

Started

Jan 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

These are patients with small rectal cancer, initially good candidates for organ preservation and whose evaluation is done by clinical and radiological examination and with the Lumeneye rectoscope

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥ 18 years * Histologically confirmed diagnosis of adenocarcinoma of the rectum, * Patient who received radiotherapy and chemotherapy (TNT) or immunotherapy * Stage cT2T3 * cN0 or cN1 (≤ 3 positive LN or size ≤ 8 mm) * no metastases * Baseline Tumour size ≤ 5 cm (MRI) * Baseline Tumour ≤ 8 from anal verge * Ability to consent. * Oral agreement after reading information letter Exclusion Criteria: * Tumour cT1 or cT4 * Baseline Tumour size \> 5cm * Invaded external sphincter or levator muscle * Tumour cN2 (\> 3 positive LN or size \> 8 mm) * Metastasis * History of Inflammatory bowel disease * Patient with a history of pelvic radiotherapy or chemotherapy * Pregnant patients * Protected adults (individuals under guardianship by court order).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rectal cancer

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, Netherlands

  • CHU de ROUEN

    Rouen, France

  • Clinique Tivoli-Ducos - Bordeaux Colorectal Institute

    Bordeaux, France

  • Humanitas Research Hospital

    Milan, Italy

  • Hôpital Européen de Marseille

    Marseille, France

  • Hôpital Saint-Antoine - APHP

    Paris, France

  • Imperial College London

    London, United Kingdom

  • University Hospital Vall D'Hebron

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.